{"entity":{"id":"neowise-biotechnology","kind":"company","name":"Neowise Biotechnology","aka":["Neowise Biotechnology (Suzhou) Co., Ltd.","新景智源生物科技"],"tldr":"Neowise Biotechnology is a Suzhou company making TCR-T cell therapies, a patient's own T cells given a receptor that recognises a marker inside cancer cells, for solid tumours. Its first product targets PRAME and a second targets a KRAS mutation.","summary":"Neowise Biotechnology (Suzhou) Co., Ltd. was registered in Suzhou in September 2020, according to the company, by returnee scientists and develops TCR-T cell therapies for solid tumours. It has built a target and TCR discovery and validation platform and a database of target-TCR pairs (more than 7,000 by 2023, by its own count), holds patents on TCRs recognising PRAME and KRAS mutations, and operates a 3,500 square metre GMP pilot facility. Its company timeline lists an angel round of tens of millions of yuan in 2020, a Series A of nearly CNY 100 million in 2021 and a Series A+ of nearly CNY 200 million in 2023. Its first registered cancer trial, NCT07266298, a phase 1 dose-escalation study of NW-101C, PRAME-targeted TCR-T cells, in advanced solid tumours in Beijing, was posted on ClinicalTrials.gov in December 2025; a second product, NW-301V, TCR-T cells for solid tumours with the KRAS G12V mutation, entered the registry in October 2026 (NCT07875920), listing pancreatic, colorectal and lung adenocarcinoma.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.neowisebio.com/"},{"label":"ClinicalTrials.gov: phase 1 trial of NW-101C (NCT07266298)","url":"https://clinicaltrials.gov/study/NCT07266298"},{"label":"ClinicalTrials.gov: phase 1 trial of NW-301V in KRAS G12V solid tumours (NCT07875920)","url":"https://clinicaltrials.gov/study/NCT07875920"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal","lung-adenocarcinoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["tcr-t"],"targets":["prame","kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Facts are from the company's Chinese-language home page timeline, read on 29 October 2026; amounts are approximate as stated ('near'). Investor names not given."],"hq":"Suzhou","country":"CN","companyType":"cell-therapy","website":"https://www.neowisebio.com/","founded":2020,"stage":"startup","investors":[],"funding":[{"round":"Series A+","year":2023,"source":"https://www.neowisebio.com/","note":"Nearly CNY 200 million, per the company timeline"},{"round":"Series A","year":2021,"source":"https://www.neowisebio.com/","note":"Nearly CNY 100 million, per the company timeline"}]},"route":"/companies/neowise-biotechnology/","neighbours":{"cancer":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"}]}}